tiprankstipranks
Trending News
More News >

Upstream Bio Holds 2025 Annual Stockholders Meeting

Story Highlights
Upstream Bio Holds 2025 Annual Stockholders Meeting

Don’t Miss TipRanks’ Half-Year Sale

Upstream Bio, Inc. ( (UPB) ) just unveiled an update.

Upstream Bio, Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025, where stockholders voted on two key proposals. The first proposal involved the election of Erez Chimovits and Marcella Kuhlman Ruddy as Class I directors, which was approved. The second proposal was the ratification of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, which was also ratified.

The most recent analyst rating on (UPB) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Upstream Bio, Inc. stock, see the UPB Stock Forecast page.

Spark’s Take on UPB Stock

According to Spark, TipRanks’ AI Analyst, UPB is a Neutral.

Upstream Bio, Inc. has a moderate stock score driven by strong technical analysis indicators suggesting positive momentum. However, the financial performance poses significant risks due to operational losses and negative cash flow. Valuation remains uncertain due to the lack of earnings and dividends, typical of a growth-phase biotechnology company.

To see Spark’s full report on UPB stock, click here.

More about Upstream Bio, Inc.

Average Trading Volume: 327,455

Technical Sentiment Signal: Hold

Current Market Cap: $623.5M

For detailed information about UPB stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1